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Background HCM has a diverse clinical spectrum and prognostication can
be challenging. N-terminal pro-brain natriuretic peptide (NTproBNP) has been
recently proposed for predicting death in HCM. Mid-regional pro-atrial natri-
uretic peptide (MRproANP) is a stable natriuretic peptide reflecting increased
atrial wall tension, with potential advantages over conventional natriuretic
peptides.
Purpose To determine the prognostic value of MRproANP in HCM
compared with NTproBNP.
Methods 491 patients with HCM were prospectively enrolled from
11 European centres in the Eurogene Heart Failure study. All patients had
clinical, ECG, echocardiographic evaluation and MRproANP and NTproBNP
measurement. Follow-up was available for 356 patients.
Results At baseline, log MRproANP and log NTproBNP were both inde-
pendently associated with age, weight, NYHA class, left ventricular ejection frac-
tion (LVEF), wall thickness (WT) and left atrial dimension (LA), but the
association was stronger between LA and MRproANP than NTproBNP and
stronger between WT and NTproBNP than MRproANP. During a median
follow-up of 24 months, 29 patients (8%) had a primary end point defined as
death, heart transplantation, left ventricular assist device (LVAD) and HF hospi-
talization. In univariate analysis, both log NTproBNP (p<0.0001) and log
MRproANP (p<0.0001) were strongly associated with primary endpoint. How-
ever, in a multiple stepwise regression analysis, entering first clinical data, then
echocardiography and then natriuretic peptides, the best model for predicting out-
come was NYHA (HR=3.1, CI 95% [1.43-6.75], p=0.004), previous HF hospi-
talization (HR 2.49, CI 95% [1.09-5.69], p=0.03), LVEF (HR=0.70, CI 95%
[0.55-0.88], p=0.003), and log MRproANP (HR=3.27, CI 95% [1.78-6.09],
p<0,0002).
Conclusions In this large cohort of HCM patients, MRproANP outper-
formed NTproBNP in the prediction of the combined event cardiac death/
transplantation/LVAD and hospitalization for heart failure.
The author hereby declares no conflict of interest
0153
Galectin 3 for risk stratification in ambulatory heart failure patients
Nils Kuster, Corentin Curinier*, Jean-Marc Davy, Florence Leclercq, Jean-
Luc Pasquie, Benoît Lattuca, Kamila Solecki, Francois Massin, Jean-
Etienne Ricci, Francois Roubille
CHU Montpellier, Cardiologie, Montpellier, France
*Corresponding author: curinier.corentin@gmail.com (Corentin Curinier)
Background Galectin-3 (Gal-3) is an emerging biomarker promising to
assess prognosis in various pathophysiological conditions including heart
failure (HF). The aim of this work was to investigate the prognosis interest of
this marker in ambulatory patients with stable HF.
Methods Patients were included in this study in 2010. All patients gave
informed consent. Clinical characteristics were registered and biomarkers
were assessed. Clinical outcomes were registered regularly by a clinical
follow-up or by phone by a dedicated physician.
Results 180 patients (mean age 72.5y±12.5y) were included. Left ventric-
ular ejection fraction was 37.1%±14.2%. Median (1st quartile – 3rd quartile)
follow-up was 42.3 (12.3-47.1) months. Survival curves were built and data
presented as means±SD when normally distributed. Patients who died during
follow up had higher Gal-3 levels at baseline. In partial correlation analysis,
Gal-3 level was negatively correlated to renal function assessed by CKD-EPI
estimated glomerular filtration rate (Spearman’s rho=-0.252, p=0.003) and
positively correlated to NT-proBNP (rho=0.367, p<0.001). Both Galectin-3
and NT-proBNP were significant predictors of all-cause mortality in univar-
iate analysis. In multivariate Cox model, New York Heart Association class
(Hazard ratio [95% CI], 1.52 [1-2,33] all cause mortality) and NT-proBNP
(2.02 [1.05-3.89], p=0,035 for all cause mortality) remained significantly and
indendently predictors of all cause and CV mortality.
Conclusion Galectin-3 provides information regarding risk of death in
ambulatory heart failure patients and is tightly correlated to NT-proBNP and
renal function.
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Background The utility of Brain Natriuretic Peptide (BNP) and cystatin C
for detecting left ventricular (LV) diastolic dysfunction after myocardial
infarction (MI) in patients without heart failure symptoms still unclear. In this
study, we investigated the relation between BNP, serum cystatin C levels and
LV diastolic dysfunction after MI in patients without systolic dysfunction.
Methods We studied 127 patients without renal dysfunctionafter first acute
coronary syndrome (ACS). LV diastolic function was assessed with
conventional Doppler, by means of mitral inflow and with tissue Doppler
echocardiography by means of mitral annulus. The ratio of early diastolic
transmitral E wave velocities to tissue Doppler mitral annulus early diastolic
E’ wave velocities (E/E’), was used to detect LV filling pressures. Patients
were divided in three groups according to E/E’ ratios <10 (group I), E/E’
ratios “between” 10 and 15 (group II) and E/E’ ratios >15 (group III). Plasma
concentrations of BNP and serum cystatin C were measured at admission.
Results The BNP and serum cystatin C levels were positively correlated
significantly with E/E’ ratio (r=0.786, p<0.001 and r=0.458, p=0.02). Patients
with elevated LV end diastolic pressure (LVEDP), defined as E/E’ >15 had
highest BNP (321±75pg/mL) and cystatin C (1.1±0.2mg/L) levels. E/E’ 10 to
15 group had a mean BNP level of 151±28pg/mL and a mean cystatin C value
of 0.78±0.1mg/L, and those with E/E’ <10 had a mean BNP value of
69±20pg/mL. A BNP value of 89pg/ml had a sensitivity of 84% and a speci-
ficity of 69% for predicting E/E’ >15.
Conclusion The assessment of the blood concentration of BNP and
cystatin C is of potential value for identification of those patients after
myocardial infarction to detect early cardiovascular changes, especially LV
diastolic dysfunction.
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Purpose To establish the usefulness of research of dispersion QT / QTc
intervals and values of cardiac biomarkers- B natriuretic peptide (BNP) and
troponin (cTnI) for early detection of cardiotoxicity in children with malig-
nancies. 
Methods Patients: 46 children (2 months-18 years), treated with anthra-
cyclines for malignancies. Control group: 20 healthy children without cardio-
vascular history. Patients and controls were evaluated by clinical exam,
surface 12 lead ECG (3 consecutive cycles of measuring the QT/QTc intervals
and QT/QTc intervals dispersion), Doppler echocardiography(echo), deter-
mining plasma levels of cardiac biomarkers BNP and cTnI.
Results Significant changes of the parameters in patients compared with
controls: 
– increasing the dispersion of the QT / QTc intervals (73% of cases, espe-
cially those with a cumulative dose of anthracyclines >250mg/m2 and in
patients with echo changes induced by anthracycline cardiotoxicity, even
only with LV diastolic dysfunction:
• the mean of QT dispersion: 80 miliseconds in patients-40 millisec in
controls; 
• the mean QTc dispersion: 87,103 millisec. in patients-55.47 millisec in
controls; 
